Korea Sees China FTA Impacting Mainly Substance Imports
This article was originally published in PharmAsia News
With South Korea set to sign an official free trade agreement with China as early as May after a tentative deal in February, the government and industries have been quickening efforts to gauge the implications for South Korea's economy. Although the impact on the pharma sector may be limited to drug substances in the near term, the government and industry are looking to capitalize on opportunities in the massive Chinese market.
You may also be interested in...
Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.
After a year full of disappointing and unexpected events, the South Korean pharma sector is hoping for a turnaround in 2020, with expected biosimilar launches in global markets, progress in drug pipelines, large IPOs and implementation of a new law on cutting-edge biologics.